cerecor-logo-final.png
Cerecor Inc. Announces Closing of $37.95 Million Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares
June 11, 2020 13:30 ET | Cerecor Inc.
ROCKVILLE, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
cerecor-logo-final.png
Cerecor Inc. Announces Pricing of $33,000,000 Public Offering of Common Stock
June 09, 2020 09:05 ET | Cerecor Inc.
ROCKVILLE, Md., June 09, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
cerecor-logo-final.png
Cerecor Inc. Announces Proposed Public Offering of Common Stock
June 08, 2020 16:01 ET | Cerecor Inc.
ROCKVILLE, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
cerecor-logo-final.png
Cerecor to Present at the Jefferies Virtual Healthcare Conference
May 29, 2020 07:00 ET | Cerecor Inc.
ROCKVILLE, Md., May 29, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies Virtual...
cerecor-logo-final.png
Cerecor Announces FDA Clearance of IND for CERC-002 in COVID-19 Induced ARDS
May 28, 2020 07:00 ET | Cerecor Inc.
Company to Initiate Multicenter, Placebo-controlled, Randomized Study in JuneTop-line Data Anticipated in Fourth Quarter 2020 ROCKVILLE, Md., May 28, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:...
cerecor-logo-final.png
Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study
May 26, 2020 07:00 ET | Cerecor Inc.
- Patients hospitalized with COVID-19 had significantly elevated levels of the inflammatory cytokine LIGHT - LIGHT was strongly linked with mortality (82%) in patients over 60 years of age -...
cerecor-logo-final.png
Cerecor Reports Q1 2020 Results and Update
May 07, 2020 06:30 ET | Cerecor Inc.
Significantly Improved Cash Position and Balance SheetClosed Aevi Merger; Transformed into Orphan and Rare Disease Biotech ROCKVILLE, Md., May 07, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:...
cerecor-logo-final.png
Cerecor Announces Changes to Board of Directors
April 24, 2020 13:45 ET | Cerecor Inc.
-Appoints Sol J. Barer, Ph.D. as Chairman of the Board- Appoints Suzanne Bruhn, Ph.D. and Joseph Miller as Directors to the Board ROCKVILLE, Md., April 24, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc....
cerecor-logo-final.png
Cerecor Announces Exploration of the Role of an Inflammatory Cytokine, LIGHT, in COVID-19 Patients with Acute Lung Injury Leading to Acute Respiratory Distress Syndrome
March 26, 2020 06:30 ET | Cerecor Inc.
ROCKVILLE, Md., March 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
cerecor-logo-final.png
Cerecor Reports 2019 Results
March 11, 2020 06:30 ET | Cerecor Inc.
-Company Transformed Into Orphan and Rare Disease Biotech-Clear Corporate Strategy with New Leadership-Significant Advancement in Pipeline and Regulatory Milestones ROCKVILLE, Md., March 11, 2020 ...